HPV疫苗下月进入国家免疫规划，技术方案待发布

Core Points - The National Health Commission of China announced that the HPV vaccine will be included in the national immunization program starting November 10, 2025, allowing girls aged 13 and above to receive two doses of the bivalent HPV vaccine for free [1][3] - The decision comes in response to the rising incidence and mortality rates of cervical cancer in China, particularly among younger women, highlighting the importance of HPV vaccination in preventing high-risk HPV infections and related diseases [3][4] - The bivalent HPV vaccine, produced by two domestic manufacturers, Xiamen Wantai and Watson Biotech's Zairun Biotech, has received prequalification from the World Health Organization, confirming its safety and efficacy [3][4] Summary by Sections Vaccination Policy - The notification specifies that only girls born after November 10, 2011, will be eligible for free vaccination, without setting an upper age limit for vaccination [4] - The World Health Organization recommends that the optimal age for HPV vaccination is between 9 and 15 years, which corresponds to the upper grades of elementary school to junior high school in China [4][5] Implementation and Logistics - Local health departments are required to collaborate with education and health authorities to assess the target population and previous vaccination records, ensuring accurate vaccine demand statistics [4] - Training for vaccination personnel will be conducted to prepare for the implementation of the immunization program, including management and monitoring of vaccine usage [4][5] Future Implications - Achieving a 90% vaccination rate among girls is essential for the goal of eliminating cervical cancer, although specific guidelines on vaccination arrangements and targets have yet to be released [5][6] - The inclusion of the HPV vaccine in the national immunization program is seen as a significant step towards reducing cervical cancer cases in the future, with potential long-term public health benefits [6]